البلد: إسرائيل
اللغة: الإنجليزية
المصدر: Ministry of Health
QUINIDINE SULFATE
REKAH PHARMACEUTICAL INDUSTRY LTD, ISRAEL
C01BA
TABLETS
QUINIDINE SULFATE 200 MG
PER OS
Required
REKAH PHARMACEUTICAL INDUSTRY LTD, ISRAEL
ANTIARRHYTHMICS, CLASS IA
Treatment of certain cardiac arrhythmias: atrial fibrillation / flutter and ventricular arrhythmias
2021-12-31
SUMMARY OF PRODUCTS CHARACTERISTICS Product Summary 1. Trade name of the Medical Product Quinidine sulfate 200 mg 2. Qualitative and Quantitative Composition Each tablets contains 200 mg of quinidine sulfate For the full list of excipient, see 6.1 3 . Pharmaceutical Form Tablet 4. Clinical Particulars 4.1 THERAPEUTIC INDICATIONS Treatment of certain cardiac arrhythmias: atrial fibrillation, atrial flutter and ventricular arrhythmias 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Adult dosage: For Atrial fibrillation and flutter, Chronic therapy to reduce recurrence: immediate-release tablet, 200 mg ORALLY every 6 h; if needed and patient tolerates, may raise dose cautiously. For Ventricular arrhythmia, Life-threatening: immediate-release tablet, 200 mg ORALLY every 6 h; if needed and patient tolerates, may raise dose cautiously. The dosage should be adapted in renal or hepatic insufficiency. Children dosage: Quinidine is not recommended in children. 4.3 CONTRAINDICATIONS Quinidine sulfate should not be given to patients with: ● Hypersensitivity to quinidine or cinchona alkaloids (quinine). ● have developed thrombocytopenic purpura during prior therapy with quinidine or quinine. Quinidine is also contraindicated in patients who, like those with myasthenia gravis, might be adversely affected by an anticholinergic agent. In the absence of a functioning artificial pacemaker, quinidine is also contraindicated in any patient whose cardiac rhythm is dependent upon a junctional or idioventricular pacemaker, including patients in complete atrioventricular block. 4.4 SPECIAL WARNING AND PRECAUTION FOR USE MORTALITY In many trials of antiarrhythmic therapy for non-life-threatening arrhythmias, active antiarrhythmic therapy has resulted in increased mortality; the risk of active therapy is probably greatest in patients with structural heart disease. In the case of quinidine used to prevent or defer recurrence of atrial flutter/fibrillation, the best available data come from a meta-analysis Pharmacological Properties / اقرأ الوثيقة كاملة